Market Research Logo

Candidiasis - Pipeline Review, H1 2015

Candidiasis - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Candidiasis - Pipeline Review, H1 2015’, provides an overview of the Candidiasis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Candidiasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Candidiasis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Candidiasis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Candidiasis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Candidiasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Candidiasis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Candidiasis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Candidiasis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Candidiasis Overview
Therapeutics Development
Pipeline Products for Candidiasis - Overview
Pipeline Products for Candidiasis - Comparative Analysis
Candidiasis - Therapeutics under Development by Companies
Candidiasis - Therapeutics under Investigation by Universities/Institutes
Candidiasis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Candidiasis - Products under Development by Companies
Candidiasis - Products under Investigation by Universities/Institutes
Candidiasis - Companies Involved in Therapeutics Development
Actavis plc
Aureogen Biosciences, Inc.
Basilea Pharmaceutica AG
Biomar Microbial Technologies
Cellceutix Corporation
Eisai Co., Ltd.
General Biologicals Corporation
Grupo Ferrer Internacional, S.A.
iCo Therapeutics Inc.
Novabiotics Ltd
NovaDigm Therapeutics, Inc.
Novartis AG
Onxeo SA
Panacela Labs, Inc.
Scynexis, Inc.
Sealife PHARMA GMBH
Sequella, Inc.
Viamet Pharmaceuticals, Inc.
Wellstat Vaccines, LLC
Candidiasis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AC-17 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
albaconazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
amphotericin b - Drug Profile
Product Description
Mechanism of Action
R&D Progress
arasertaconazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AUGC-10 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AUGC-15 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
candida vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
candidiasis vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
E-1210 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
E-1211 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
isavuconazonium sulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
miconazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
mutanobactins - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NDV-3 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NDV-3A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NP-339 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PAC-113 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pegylated amphotericin B - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PEV-7 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PMX-1408 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PMX-1502 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PMX-1570 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PMX-1576 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PMX-1591 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PMX-1625 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PMX-30016 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PMX-519 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Prof-002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Peptides for Oropharyngeal Candidiasis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SCY-078 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SLP-0901 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SLP-0904 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Candidiasis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Candidiasis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Candidiasis and Cryptococcosis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Cryptococcosis and Candidiasis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Fungal Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Aspergillosis and Candidiasis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Candidiasis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Candidiasis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Fungal Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SQ-109 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VT-1161 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
XELRYX-3 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Candidiasis - Recent Pipeline Updates
Candidiasis - Dormant Projects
Candidiasis - Discontinued Products
Candidiasis - Product Development Milestones
Featured News & Press Releases
Nov 03, 2014: Basilea Reports Granting Of U.S. Orphan Drug Designation To Isavuconazole For The Treatment Of Invasive Candidiasis
Oct 16, 2014: Basilea Reports Protocol Amendment Resulting In Earlier Completion Of Isavuconazole Phase 3 Invasive Candidiasis Study
Sep 10, 2014: Data for Viamet’s VT-1161 Presented at ICAAC 2014
Jul 16, 2014: FDA Grants Astellas Qualified Infectious Disease Product Designation for Isavuconazole for the Treatment of Invasive Candidiasis
Jul 10, 2014: Viamet Reports Additional Positive Interim Results of Phase 2 Study of VT-1161 in Patients with Moderate to Severe Acute Vulvovaginal Candidiasis
Apr 01, 2014: BioAlliance Pharma provides an update on its partnerships for Loramyc/Oravig
Feb 18, 2014: Viamet Reports Positive Interim Results of Phase 2 Study of VT-1161
Nov 18, 2013: Cellceutix Identifies PMX-1408 as treatment Gram-Negative and Candida Fungal Infections
Nov 18, 2013: Cellceutix Identifies Drug Candidate for Candida Fungal Infections
Sep 26, 2013: NovaDigm Therapeutics Initiates Phase 1b/2a Clinical Trial with NDV-3 Vaccine in Recurrent Vulvovaginal Candidiasis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Candidiasis, H1 2015
Number of Products under Development for Candidiasis - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2015
Candidiasis - Pipeline by Actavis plc, H1 2015
Candidiasis - Pipeline by Aureogen Biosciences, Inc., H1 2015
Candidiasis - Pipeline by Basilea Pharmaceutica AG, H1 2015
Candidiasis - Pipeline by Biomar Microbial Technologies, H1 2015
Candidiasis - Pipeline by Cellceutix Corporation, H1 2015
Candidiasis - Pipeline by Eisai Co., Ltd., H1 2015
Candidiasis - Pipeline by General Biologicals Corporation, H1 2015
Candidiasis - Pipeline by Grupo Ferrer Internacional, S.A., H1 2015
Candidiasis - Pipeline by iCo Therapeutics Inc., H1 2015
Candidiasis - Pipeline by Novabiotics Ltd, H1 2015
Candidiasis - Pipeline by NovaDigm Therapeutics, Inc., H1 2015
Candidiasis - Pipeline by Novartis AG, H1 2015
Candidiasis - Pipeline by Onxeo SA, H1 2015
Candidiasis - Pipeline by Panacela Labs, Inc., H1 2015
Candidiasis - Pipeline by Scynexis, Inc., H1 2015
Candidiasis - Pipeline by Sealife PHARMA GMBH, H1 2015
Candidiasis - Pipeline by Sequella, Inc., H1 2015
Candidiasis - Pipeline by Viamet Pharmaceuticals, Inc., H1 2015
Candidiasis - Pipeline by Wellstat Vaccines, LLC, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Candidiasis Therapeutics - Recent Pipeline Updates, H1 2015
Candidiasis - Dormant Projects, H1 2015
Candidiasis - Dormant Projects (Contd..1), H1 2015
Candidiasis - Dormant Projects (Contd..2), H1 2015
Candidiasis - Discontinued Products, H1 2015
List of Figures
Number of Products under Development for Candidiasis, H1 2015
Number of Products under Development for Candidiasis - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report